TORONTO, August 13, 2018 – Easton Pharmaceuticals Inc. (OTC: EAPH) (the "Company"), announces that Mr. Panagis "Panos" Alivizatos resigned due to personal reasons from the Company’s Board of Directors, effective as of Monday, August 13th 2018.
Mr. Alivizatos joined the Easton Board in late June, as part of the Company’s plan to restructure and pursue more lucrative projects, globally.
The Company’s CEO, Mr. Evan Karras, stated “It is with great regret that Panagis cannot continue to be part of our team, due to personal reasons. Easton would like to thank him for his brief service and would further like to wish him success in his future endeavours”. Mr. Karras further stated “This change does not affect the Company’s plan nor does it interfere with the business opportunities that the Company has been working on”.
Further news on the Company’s plans will be announced in the next few days.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other industries, which includes soil, aggregate, recycling, pharmaceuticals, diagnostic and other growing industries, such as real estate, hospitality, gaming, commodities, mining, transportation, maritime and marine services. The Company previously developed and owned an FDA-approved wound healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, through BMV Medica S.A., and together own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which are to be distributed by Bayer. In addition, a generic cancer drug line is currently in the approval process for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system.
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact: Investor Relations
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: eastonpharma@protonmail.com